Literature DB >> 1818225

Immunotherapy of cryptosporidiosis in immunodeficient animal models.

L E Perryman1, J M Bjorneby.   

Abstract

Immunotherapy for persistent infection caused by Cryptosporidium parvum was attempted in two immunodeficient animal models. BALB/c Athymic (nude) mice were infected with two oral doses of 2 x 10(7) C. parvum oocysts, and subsequently treated with monoclonal antibody (MAb) 17.41 that neutralizes sporozoites and merozoites. Persistent infection was established in all exposed mice. Daily oral treatment with MAb 17.41 for 10 days significantly reduced (p less than 0.005) the number of C. parvum organisms observed by microscopic study of intestinal tracts of infected mice. Young horses with severe combined immunodeficiency (SCID) also developed persistent infection following oral exposure with 10(8) C. parvum oocysts. In contrast to nude mice, SCID foals exhibited diarrhea associated with oocyst shedding. Two foals were treated orally with MAb 18.44 and immune serum, both of which neutralized C. parvum sporozoites and merozoites. Oocyst shedding patterns did not significantly differ from those in five SCID foals treated with nonimmune reagents. The results obtained indicate that SCID foals are a useful large animal model of clinical disease associated with persistent C. parvum infection, and that nude mice are a convenient animal model for testing therapeutic potential of antibodies in persistent cryptosporidial infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818225

Source DB:  PubMed          Journal:  J Protozool        ISSN: 0022-3921


  5 in total

1.  Profiles of healing and nonhealing Cryptosporidium parvum infection in C57BL/6 mice with functional B and T lymphocytes: the extent of gamma interferon modulation determines the outcome of infection.

Authors:  C M Theodos; K L Sullivan; J K Griffiths; S Tzipori
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

2.  Activation of intestinal intraepithelial T lymphocytes in calves infected with Cryptosporidium parvum.

Authors:  C R Wyatt; E J Brackett; L E Perryman; A C Rice-Ficht; W C Brown; K I O'Rourke
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

3.  Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection.

Authors:  F J Enriquez; M W Riggs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Effect of orally administered monoclonal antibody on persistent Cryptosporidium parvum infection in scid mice.

Authors:  L E Perryman; K A Kegerris; P H Mason
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

5.  An intestinal xenograft model for Cryptosporidium parvum infection.

Authors:  J D Thulin; M S Kuhlenschmidt; M D Rolsma; W L Current; H B Gelberg
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.